药代动力学-话题@MedSci

#药代动力学#

48篇内容 | 2828人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1351262, encodeId=e47713512622b, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学, objectType=article, longId=125692, objectId=336a1256926c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=336a1256926c, replyNumber=0, likeNumber=86, createdTime=2018-01-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=336a1256926c, moduleTitle=Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=336a1256926c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351261, encodeId=5ce81351261a6, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, objectType=article, longId=122554, objectId=1415122554e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1415122554e2, replyNumber=0, likeNumber=76, createdTime=2017-12-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1415122554e2, moduleTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1415122554e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351260, encodeId=b3de135126041, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=Invest Ophthalmol Vis Sci：PET可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征！, objectType=article, longId=100608, objectId=0a261006081d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a261006081d, replyNumber=0, likeNumber=84, createdTime=2017-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a261006081d, moduleTitle=Invest Ophthalmol Vis Sci：PET可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a261006081d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351259, encodeId=a84c13512590c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征, objectType=article, longId=100541, objectId=5f5410054125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5410054125, replyNumber=0, likeNumber=81, createdTime=2017-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5410054125, moduleTitle=CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5410054125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351258, encodeId=3deb135125808, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？, objectType=article, longId=100535, objectId=2246100535ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2246100535ac, replyNumber=0, likeNumber=44, createdTime=2017-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2246100535ac, moduleTitle=CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2246100535ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351257, encodeId=bcff135125e7f, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=CLIN PHARMACOKINET：Necitumumab在癌症患者中的群体药代动力学如何？, objectType=article, longId=100531, objectId=077010053178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=077010053178, replyNumber=0, likeNumber=37, createdTime=2017-06-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=077010053178, moduleTitle=CLIN PHARMACOKINET：Necitumumab在癌症患者中的群体药代动力学如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=077010053178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351256, encodeId=aed31351256c5, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=PLos One：庆大霉素在感染性心内膜炎治疗中的药代动力学模型, objectType=article, longId=98309, objectId=51469830949, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51469830949, replyNumber=0, likeNumber=67, createdTime=2017-05-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51469830949, moduleTitle=PLos One：庆大霉素在感染性心内膜炎治疗中的药代动力学模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51469830949)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351255, encodeId=933013512554a, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究, objectType=article, longId=66123, objectId=e4cb6612395, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4cb6612395, replyNumber=0, likeNumber=64, createdTime=2016-04-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4cb6612395, moduleTitle=J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4cb6612395)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351254, encodeId=089313512545c, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, objectType=article, longId=50462, objectId=d8575046299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8575046299, replyNumber=0, likeNumber=56, createdTime=2015-05-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8575046299, moduleTitle=Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8575046299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351253, encodeId=5d05135125317, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系, objectType=article, longId=47740, objectId=d2704e740fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2704e740fd, replyNumber=0, likeNumber=89, createdTime=2015-03-06, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2704e740fd, moduleTitle=DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2704e740fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351252, encodeId=fa6313512524d, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, objectType=article, longId=35644, objectId=12f33564411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f33564411, replyNumber=0, likeNumber=68, createdTime=2014-06-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f33564411, moduleTitle=ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f33564411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351251, encodeId=18ec13512510e, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=临床药代动力学试验的常见设计类型与统计分析, objectType=article, longId=34682, objectId=0673346820f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0673346820f, replyNumber=0, likeNumber=57, createdTime=2014-05-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0673346820f, moduleTitle=临床药代动力学试验的常见设计类型与统计分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0673346820f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351250, encodeId=46951351250ff, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=CCP：研究发现阿法替尼群体药代动力学新模型, objectType=article, longId=34275, objectId=5bdc342e5e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bdc342e5e9, replyNumber=0, likeNumber=65, createdTime=2014-05-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bdc342e5e9, moduleTitle=CCP：研究发现阿法替尼群体药代动力学新模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bdc342e5e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351249, encodeId=3a8313512498a, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=EMEA关于肾功能损害病人药代动力学评价指南说明, objectType=article, longId=31896, objectId=614931896eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614931896eb, replyNumber=0, likeNumber=63, createdTime=2014-03-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614931896eb, moduleTitle=EMEA关于肾功能损害病人药代动力学评价指南说明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614931896eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351248, encodeId=c5581351248f7, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=EMEA关于肝功能损害病人的药代动力学评价指南, objectType=article, longId=31895, objectId=d464318956c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d464318956c, replyNumber=0, likeNumber=75, createdTime=2014-03-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d464318956c, moduleTitle=EMEA关于肝功能损害病人的药代动力学评价指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d464318956c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1351247, encodeId=1ea2135124e62, content=<a href='/topic/show?id=9ac28e2893e' target=_blank style='color:#2F92EE;'>#药代动力学#</a>, objectTitle=Trimel公司Tefina药代动力学研究结果发布, objectType=article, longId=5762, objectId=954c5e624c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954c5e624c, replyNumber=0, likeNumber=75, createdTime=2012-04-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954c5e624c, moduleTitle=Trimel公司Tefina药代动力学研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954c5e624c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

药代动力学

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

Pharmaceut Res:茚地那韦部分通过抑制多药和毒素排出蛋白1（MATE1）改变拉米夫定的药代动力学

2018-01-07

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果

2017-12-08

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

Invest Ophthalmol Vis Sci：PET可以作为非侵入性的手段来研究玻璃体内注射的药代动力学特征！

2017-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

CLIN PHARMACOKINET：1型糖尿病患者速效型胰岛素的药代动力学和药效学特征

2017-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

CLIN PHARMACOKINET：抗逆转录病毒药物和CYP2C9 / CYP2C19多态性对Etravirine药代动力学的影响？

2017-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

CLIN PHARMACOKINET：Necitumumab在癌症患者中的群体药代动力学如何？

2017-06-04

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

PLos One：庆大霉素在感染性心内膜炎治疗中的药代动力学模型

2017-05-11

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

J Acq Immun Def Synd：Dolutegravir对二甲双胍药代动力学的影响研究

2016-04-07

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

Invest New Drugs：dacomitinib(pan-HER 抑制剂)用于晚期头颈部鳞状细胞癌的药代动力学评价

2015-05-10

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

DRCP：亚洲2型糖尿病患者利拉鲁肽的药代动力学和剂量暴露反应的联系

2015-03-06

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

ASCO 2014：5-FU和顺铂治疗晚期鼻咽癌的药代动力学和遗传药理学分析

2014-06-02

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

临床药代动力学试验的常见设计类型与统计分析

2014-05-15

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

CCP：研究发现阿法替尼群体药代动力学新模型

2014-05-07

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

EMEA关于肾功能损害病人药代动力学评价指南说明

2014-03-15

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

EMEA关于肝功能损害病人的药代动力学评价指南

2014-03-15

zhaojie88 (审核中...)

前往app查看评论内容

#药代动力学#

Trimel公司Tefina药代动力学研究结果发布

2012-04-27

科室
- - 订阅+
  - 更多科室
工具
服务